Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus

Detalles Bibliográficos
Autores principales: Jin, Zhili, Wang, Yini, Wang, Jingshi, Zhang, Jia, Wu, Lin, Wang, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647074/
https://www.ncbi.nlm.nih.gov/pubmed/30830248
http://dx.doi.org/10.1007/s00277-019-03647-5
_version_ 1783437649282859008
author Jin, Zhili
Wang, Yini
Wang, Jingshi
Zhang, Jia
Wu, Lin
Wang, Zhao
author_facet Jin, Zhili
Wang, Yini
Wang, Jingshi
Zhang, Jia
Wu, Lin
Wang, Zhao
author_sort Jin, Zhili
collection PubMed
description
format Online
Article
Text
id pubmed-6647074
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-66470742019-08-06 Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus Jin, Zhili Wang, Yini Wang, Jingshi Zhang, Jia Wu, Lin Wang, Zhao Ann Hematol Letter to the Editor Springer Berlin Heidelberg 2019-03-04 2019 /pmc/articles/PMC6647074/ /pubmed/30830248 http://dx.doi.org/10.1007/s00277-019-03647-5 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Jin, Zhili
Wang, Yini
Wang, Jingshi
Zhang, Jia
Wu, Lin
Wang, Zhao
Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
title Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
title_full Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
title_fullStr Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
title_full_unstemmed Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
title_short Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
title_sort long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active epstein–barr virus
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647074/
https://www.ncbi.nlm.nih.gov/pubmed/30830248
http://dx.doi.org/10.1007/s00277-019-03647-5
work_keys_str_mv AT jinzhili longtermsurvivalbenefitofruxolitinibinapatientwithrelapsedrefractorychronicactiveepsteinbarrvirus
AT wangyini longtermsurvivalbenefitofruxolitinibinapatientwithrelapsedrefractorychronicactiveepsteinbarrvirus
AT wangjingshi longtermsurvivalbenefitofruxolitinibinapatientwithrelapsedrefractorychronicactiveepsteinbarrvirus
AT zhangjia longtermsurvivalbenefitofruxolitinibinapatientwithrelapsedrefractorychronicactiveepsteinbarrvirus
AT wulin longtermsurvivalbenefitofruxolitinibinapatientwithrelapsedrefractorychronicactiveepsteinbarrvirus
AT wangzhao longtermsurvivalbenefitofruxolitinibinapatientwithrelapsedrefractorychronicactiveepsteinbarrvirus

Ejemplares similares